Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of GRIFFIN (AFT-29) Among Clinically Relevant Subgroups
- Citation:
- Blood vol 140 (suppl 1) 7278–81
- Meeting Instance:
- ASH 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- AFT
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 4146
- Pharmas:
- Janssen
- Grants:
- Corr. Author:
- Authors:
- Ajai Chari Jonathan L. Kaufman Jacob Laubach Douglas W. Sborov Brandi Reeves Cesar Rodriguez Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr. Nitya Nathwani Nina Shah Naresh Bumma Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Huiling Pei Annelore Cortoos Sharmila Patel Thomas S. Lin Paul G. Richardson Saad Z Usmani Peter M. Voorhees
- Networks:
- CA043, CA136, CA249, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, OR013
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: